As of 6 Nov 2026, Veerhealth Care trades at 65.0× trailing earnings, above the industry P/E of 28.7×, and the shares are 10% below their 52-week high. Its ROCE of 5.3% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 34% a year over 3 years while net profit fell 30%. Debt is 0.20× equity. It is a small-cap company with a market cap of ₹94 Cr, ranked 121st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 171% over the past year.
- ₹49.49
- ₹49.49
- ₹46.79
- ₹49.25
- 1.1 L
Health check
- ReturnsAhead
+171.3% over a year, better than 7 of 7 peers.
- Price tagPricier
P/E 65.0 vs industry 28.7.
- GrowthSteady
Sales +34.4%, profit −29.9% a year over 3 years.
- ProfitabilityWeak
ROCE 5.3% vs peer median 17.9%.
- Balance sheetFair
Debt 0.20× equity, interest covered 4.4×, Piotroski 7 of 9.
- Red flags2 to check
Return on equity is low at 2.4%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹94 Cr
- Small cap
- P/E
- 65.0
- Industry 28.7
- Price to book
- 4.01
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 2.4%
- Peers 14.7%
- ROCE
- 5.3%
- Peers 17.9%
- Debt to equity
- 0.20
- Debt ₹4.58 Cr
- EPS (TTM)
- ₹0.72
- OPM (TTM)
- 7.8%
- Net margin 2.9%
- Sales growth
- +455.7%
- Latest quarter vs a year ago
- Profit growth
- +409.8%
- Latest quarter vs a year ago
- Price to sales
- 1.76
- EV/EBITDA 20.8
Strengths and risks
Strengths
- Quarterly profit up 409.8% on a year ago.
- Quarterly sales up 455.7% on a year ago.
Risks to check
- Return on equity is low at 2.4%.
- P/E of 65.0 against an industry P/E of 28.7.
About Veerhealth Care
Veerhealth Care Limited engages in manufacturing and markets oral care, skincare, personal care, cosmetic, and Ayurvedic products and formulations in India. The company offers skincare products, such as creams, face serum, facewash, toners, lip balms, and scrubs; body care products, including bodywash, bath salts, lotions, handwash, and soaps; hair oils, hair combs, hair serum, shampoos, and conditioners; Ayurvedic Wellness, such as syrups, tablets, and…
- Headquarters
- Mumbai
- Employees
- 64
- Sector
- Healthcare
- ISIN
- INE882C01035
- Website
- veerhealthcare.net
Price range
- Avg volume (3M)
- 1.1 L
- 1-year return
- plus 171.3%
- From 52-week high
- minus 10.0%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| VEERHEALTHVeerhealth Care | 46.79 | minus 4.99% | 94 | 65.0 | 4.01 | 5.3% | 2.4% | 8.3% | 34.4% | −29.9% | 0.00% | plus 171.3% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 4.5 | 4 | 7.3 | 16.8 | 24.9 | |
| 4.5 | 3.4 | 6.3 | 16 | 23 | |
| −0 | 0.5 | 0.9 | 0.7 | 1.9 | |
| −0.8% | 13.4% | 13.0% | 4.4% | 7.7% | |
| 0.7 | 0.2 | 0 | 0.2 | 0.2 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | |
| 0.3 | 0.3 | 0.4 | 0.3 | 0.4 | |
| – | – | – | −0.3 | – | |
| 0.2 | 0.3 | 0.5 | 0.2 | 1.5 | |
| – | 26.3% | 18.2% | 296.3% | 16.9% | |
| 0.2 | 0.3 | 0.4 | −0.4 | 1.2 | |
| 0.12 | 0.13 | 0.20 | -0.18 | 0.57 |
Profit & loss
- Sales CAGR 3Y
- +34.4%
- Profit CAGR 3Y
- −29.9%
- EPS CAGR 3Y
- −29.2%
- ROE
- 2.4%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 13.2 | 13.2 | 16.6 | 32.1 | |
| – | minus 0.0% | +25.5% | +93.4% | |
| 12.4 | 12.6 | 15.6 | 29.3 | |
| 0.8 | 0.6 | 1 | 2.8 | |
| 6.1% | 4.6% | 6.0% | 8.8% | |
| 0.9 | 1.4 | 0.5 | 0.4 | |
| – | 0 | 0.1 | 0.4 | |
| 0.6 | 0.7 | 0.9 | 1.3 | |
| −0 | −0 | 0.1 | −0.3 | |
| 1.1 | 1.3 | 0.6 | 1.3 | |
| −41.6% | 68.3% | 37.0% | 56.8% | |
| 1.6 | 0.4 | 0.4 | 0.5 | |
| – | minus 74.3% | minus 3.6% | +39.0% | |
| 0.76 | 0.21 | 0.20 | 0.27 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 10 | 20 | 20 | 20 | |
| 11.4 | 1.8 | 2.2 | 2.9 | |
| – | – | 4.9 | 4.6 | |
| 3.8 | 6.3 | 6.6 | 16.7 | |
| 25.3 | 28.1 | 33.8 | 44.2 | |
| 12 | 12 | 19.9 | 23.4 | |
| 2.1 | – | 0 | 0 | |
| 3.6 | 0.2 | 1.2 | 0.5 | |
| 7.5 | 15.9 | 12.7 | 20.2 | |
| 25.3 | 28.1 | 33.8 | 44.2 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −0.7 | 2.9 | 4.5 | 4.2 | |
| −1.8 | −0.3 | −8.2 | −4.4 | |
| 5.7 | −6 | 4.6 | −0.5 | |
| 3.2 | −3.4 | 0.9 | −0.7 | |
| −2.1 | −0.8 | −8.8 | −4.9 | |
| −2.8 | 2.1 | −4.3 | −0.7 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.